Brokerages Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) PT at $7.40

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $7.40.

ATNM has been the subject of several recent research reports. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. Finally, Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers lifted its position in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at approximately $142,000. Marshall Wace LLP lifted its holdings in shares of Actinium Pharmaceuticals by 67.9% during the 2nd quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter worth approximately $356,000. Finally, The Manufacturers Life Insurance Company bought a new position in Actinium Pharmaceuticals in the second quarter valued at approximately $92,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $1.22 on Friday. Actinium Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $10.24. The firm has a market cap of $38.06 million, a P/E ratio of -0.88 and a beta of 0.12. The firm’s 50-day simple moving average is $1.30 and its 200 day simple moving average is $2.15.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).